NCT00727727View on ClinicalTrials.gov

SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)

CompletedOBSERVATIONAL
Enrollment

750

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Parkinson's Disease
Interventions
DRUG

Piribedil

Trial Locations (2)

22880

Medical Practice for Neurology, Wedel

01307

Medical Practice for Neurology, Dresden

Sponsors
All Listed Sponsors
lead

Desitin Arzneimittel GmbH

INDUSTRY

NCT00727727 - SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K) | Biotech Hunter | Biotech Hunter